Aclarion, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Aclarion, Inc. (NASDAQ: ACON) is a healthcare technology company that leverages magnetic resonance spectroscopy (MRS), proprietary biomarkers, and augmented intelligence algorithms to deliver noninvasive SaaS solutions for optimizing clinical treatments in the chronic low back and neck pain market; its flagship NOCISCAN platform analyzes the chemical composition of intervertebral discs to distinguish painful from nonpainful ones, generating individualized NOCI+/NOCI- scores on a 0-10 scale and supporting personalized treatment plans with reported 97% surgical success rates when pain-positive discs are addressed; the suite includes the NOCISCAN MRS Exam Protocol for extended lumbar MRI scans using commercial MRS pulse sequences, data transfer tools such as AMBRA Healthcare imaging platform and NOCIWEB interface, and the Post-Processor Suite featuring NOCICALC for raw data processing into spectra and biomarker calculations plus NOCIGRAM for NOCISCORE generation. Founded in 2008 and headquartered in Broomfield, Colorado, the company primarily serves physicians, radiologists, and healthcare providers in the United States while expanding commercially into the United Kingdom; it targets the $134.5 billion U.S. low back and neck pain sector affecting approximately 266 million people globally with degenerative spine disease. Recent developments include raising over $20 million in Q1 2025 to maintain nearly $15 million in cash reserves with zero debt, achieving full Nasdaq compliance for bid price and shareholder equity, fully funding the pivotal CLARITY trial with interim results expected in Q2 2026 and first patient enrollments at University of Miami Health System in September 2025, securing additional payer approvals in England covering 5.2 million lives, appointing Dan Isherwood as UK Commercial Director in November 2025 and Jason Brosniak as U.S. Eastern Commercial Director in December 2025 to drive adoption, publishing a NOCISCAN article in the International Journal of Spine Surgery's special pain issue on December 4, 2025, winning "Rising Star" at the 2025 Digital Health Awards, and pursuing partnerships with imaging providers like RadNet and MRI manufacturers.
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion Announces Texas Spine Care Center as New CLARITY Site
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Aclarion Rejects Echo Lake Capital's Unsolicited Acquisition Proposal
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
Aclarion, Inc. Comments on Echo Lake Capital's Letter and Unsolicited Proposal
Echo Lake Capital Offers To Acquire Aclarion Inc.
Aclarion (ACON) Upgraded to Buy: Here's Why
Aclarion, Inc. (ACON) Reports Q1 Loss, Misses Revenue Estimates
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption